InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,200.80
(
-0.33%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
-0.66%
)
Bitcoin
60,154.55
(
-2.36%
)
Post# of 252426
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: DewDiligence post# 61791

Wednesday, 10/28/2009 9:42:21 AM

Wednesday, October 28, 2009 9:42:21 AM

Post# of 252426
VRTX - interim analysis of data from 94 patients from Study 107

http://investors.vrtx.com/releasedetail.cfm?ReleaseID=419250

* 57% of prior treatment null responder patients achieved an SVR with a 48-week telaprevir-based regimen
* 90% of prior treatment relapsers and 55% of prior treatment partial responders achieved an SVR with 24-week or 48-week telaprevir-based regimens
* Results provide further support for the ongoing Phase 3 registration study, REALIZE, in treatment-failure patients
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up